MAPK1 and cancer: The small-molecule inhibitor BCI ((E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one) has been reported to inhibit MKP3, thereby enhancing ERK signaling and promoting selective cytotoxicity in cancer cells.